[go: up one dir, main page]

MX2012005013A - Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel. - Google Patents

Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel.

Info

Publication number
MX2012005013A
MX2012005013A MX2012005013A MX2012005013A MX2012005013A MX 2012005013 A MX2012005013 A MX 2012005013A MX 2012005013 A MX2012005013 A MX 2012005013A MX 2012005013 A MX2012005013 A MX 2012005013A MX 2012005013 A MX2012005013 A MX 2012005013A
Authority
MX
Mexico
Prior art keywords
acceptable salts
injuries
damages
prevention
pterostilben
Prior art date
Application number
MX2012005013A
Other languages
English (en)
Inventor
Ariquel Jose Maria Estrella
Miralles Miguel A Asensi
Original Assignee
Green Molecular S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Molecular S L filed Critical Green Molecular S L
Publication of MX2012005013A publication Critical patent/MX2012005013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/164—Unsaturated ethers containing six-membered aromatic rings
    • C07C43/166—Unsaturated ethers containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere al uso de PTER, o cualquiera de sus sales aceptables, opcionalmente, en combinación con QUER, o cualquiera de sus sales aceptables, para la fabricación de composiciones farmacéuticas para prevenir y/o tratar enfermedades, daños o lesiones de la piel. Esos procedimientos de prevención y/o tratamiento comprenden la administración de una cantidad eficaz de una composición que comprende PTER como compuesto activo, o cualquiera de sus sales aceptables, opcionalmente, en combinación con QUER, o cualquiera de sus sales aceptables, a un sujeto. La presente invención también se refiere a las composiciones, en sí, que comprenden PTER como compuesto activo, o cualquiera de sus sales aceptables, opcionalmente, en combinación con QUER, o cualquiera de sus sales aceptables, caracterizadas por estar formuladas en forma de liposomas, y al procedimiento para la preparación de dichas formulaciones en liposomas.
MX2012005013A 2009-10-30 2010-10-29 Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel. MX2012005013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174717A EP2322159A1 (en) 2009-10-30 2009-10-30 Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
PCT/EP2010/066544 WO2011051483A1 (en) 2009-10-30 2010-10-29 Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures

Publications (1)

Publication Number Publication Date
MX2012005013A true MX2012005013A (es) 2012-08-15

Family

ID=42320589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005013A MX2012005013A (es) 2009-10-30 2010-10-29 Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel.

Country Status (14)

Country Link
US (3) US20130136778A1 (es)
EP (2) EP2322159A1 (es)
JP (2) JP2013509385A (es)
KR (1) KR101795495B1 (es)
CN (1) CN102639126B (es)
AU (2) AU2010311326B2 (es)
BR (1) BR112012010070A2 (es)
CA (1) CA2778151C (es)
DK (1) DK2493462T3 (es)
ES (1) ES2432236T3 (es)
IL (1) IL219318A (es)
MX (1) MX2012005013A (es)
RU (1) RU2578031C2 (es)
WO (1) WO2011051483A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841350B2 (en) * 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
JP5901547B2 (ja) * 2012-03-28 2016-04-13 富士フイルム株式会社 組成物、これを含む皮膚外用剤、又は機能性食品
ES2506243T3 (es) * 2012-09-05 2014-10-13 Psoriasis+Creams Sweden Ab Composición para tratar la psoriasis
CA2893342A1 (en) * 2012-12-06 2014-06-12 D & J Rosee Inc. Topical liposome compositions containing phenolic anti-inflammatory agents and their methods of preparation
US20160067193A1 (en) * 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
US9980924B2 (en) 2014-09-04 2018-05-29 The Regents Of The University Of California Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
JP2018517774A (ja) 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
CN108653303A (zh) * 2018-04-02 2018-10-16 青岛科技大学 一种具有提供弱酸性胶束微环境的高稳定型紫檀芪滴眼液及其制备方法
CN108653304A (zh) * 2018-04-04 2018-10-16 青岛科技大学 一种紫檀芪纳米胶束外用凝胶及其制备方法
JP2020069470A (ja) * 2018-10-29 2020-05-07 株式会社げんてん本店 リポソームの製造方法、及び、リポソーム含有液の製造方法
KR20200052191A (ko) 2018-11-06 2020-05-14 한국식품연구원 후각수용체 특이적 리간드 및 그 용도
WO2020263189A1 (en) * 2019-06-25 2020-12-30 Agency For Science, Technology And Research Phenols that decrease lipid production in sebocytes
JP7493176B2 (ja) * 2020-04-14 2024-05-31 国立研究開発法人産業技術総合研究所 放射線被ばくによる皮膚炎発生の予測
CN115040420A (zh) * 2022-07-18 2022-09-13 云南贝泰妮生物科技集团股份有限公司 一种紫檀芪脂质体及其制备方法
WO2024086100A1 (en) * 2022-10-20 2024-04-25 Innovation Hammer Llc Methods and formulations for mitigating damaging effects from exposure to uv radiation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944313A (ja) * 1982-09-07 1984-03-12 Yakult Honsha Co Ltd 抗菌性組成物
US5139803A (en) * 1989-02-09 1992-08-18 Nabisco, Inc. Method and liposome composition for the stabilization of oxidizable substances
AU2094901A (en) * 1999-12-16 2001-06-25 Johnson & Johnson Consumer Companies, Inc. Compositions containing a retinoid and a stilbene for skin care
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
DE10161253A1 (de) * 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
CN1269782C (zh) * 2003-10-24 2006-08-16 中国科学院广州化学研究所 紫檀芪的合成方法
ES2246165B1 (es) * 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US20060057231A1 (en) * 2004-08-19 2006-03-16 Rimando Agnes M Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
WO2008067928A1 (en) 2006-12-04 2008-06-12 Isdin S.A. Uv absorbing compositions containing a pyrrolyltriazine
US20090047309A1 (en) * 2007-08-13 2009-02-19 Maes Daniel H Cosmetic methods and compositions for repairing human skin
RU2357724C1 (ru) * 2007-10-22 2009-06-10 Институт химии нефти Сибирского отделения Российской академии наук Способ получения магниточувствительных липосом
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
CN101912377A (zh) * 2010-08-10 2010-12-15 王晓琴 紫檀芪在制备抗宫颈癌药物中的应用

Also Published As

Publication number Publication date
US20180008555A1 (en) 2018-01-11
RU2012122241A (ru) 2013-12-10
WO2011051483A1 (en) 2011-05-05
EP2493462A1 (en) 2012-09-05
JP5905979B2 (ja) 2016-04-20
EP2493462B1 (en) 2013-07-24
KR20120094167A (ko) 2012-08-23
KR101795495B1 (ko) 2017-12-01
CN102639126A (zh) 2012-08-15
US20160158164A1 (en) 2016-06-09
CA2778151A1 (en) 2011-05-05
JP2016006060A (ja) 2016-01-14
DK2493462T3 (da) 2013-10-28
ES2432236T3 (es) 2013-12-02
IL219318A (en) 2016-03-31
US20130136778A1 (en) 2013-05-30
RU2578031C2 (ru) 2016-03-20
AU2016234952B2 (en) 2018-08-16
CA2778151C (en) 2017-03-07
AU2010311326A1 (en) 2012-05-17
JP2013509385A (ja) 2013-03-14
BR112012010070A2 (pt) 2016-05-31
EP2322159A1 (en) 2011-05-18
AU2010311326B2 (en) 2016-10-06
CN102639126B (zh) 2018-07-06
AU2016234952A1 (en) 2016-10-13
IL219318A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
MX2012005013A (es) Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel.
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
BR112014007902A2 (pt) composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
MX341684B (es) Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel.
MX2011009847A (es) Agentes antihelminticos y su uso.
GT201200038A (es) Composicion para tratar la fibrosis quistica
CO6710926A2 (es) Compuestos de n-heteroarilo
DOP2016000253A (es) Nuevos compuestos
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
CL2013000866A1 (es) Sales cristalinas oxalato y fosfato del conjugado naloxolpolietilenglicol; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento del dolor.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
NI201900063A (es) Amidas aromáticas de ácido carboxílico
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CO6761349A2 (es) Proteína antimicrobiana
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt

Legal Events

Date Code Title Description
FG Grant or registration